EyePoint Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 EyePoint Pharmaceuticals Inc 公司

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

EyePoint Pharmaceuticals Inc簡介



公司代碼EYPT

公司名稱EyePoint Pharmaceuticals Inc

上市日期Jan 27, 2005

CEODuker (Jay S)

員工數量165

證券類型Ordinary Share

年結日Jan 27

公司地址480 Pleasant Street, Suite C400

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02472

電話16179265000

網址https://eyepointpharma.com/

公司代碼EYPT

上市日期Jan 27, 2005

CEODuker (Jay S)

EyePoint Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

Dr. Goeran A. Ando, M.D.

Non-Executive Independent Chairman of the Board

--

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

--

Mr. George Elston

Chief Financial Officer, Executive Vice President

--

Mr. Stern

Investor Relations

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

收入明細

單位: USD更新時間: 1月6日週二

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

YUTIQ

3.10M

7.16%

地區USD

名稱

營收

佔比

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

業務

地區

業務USD

名稱

營收

佔比

YUTIQ

3.10M

7.16%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

其他

64.82%

持股股東

佔比

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

其他

64.82%

股東類型

持股股東

佔比

Hedge Fund

32.77%

Investment Advisor

25.06%

Investment Advisor/Hedge Fund

20.85%

Research Firm

4.43%

Private Equity

3.39%

Individual Investor

2.96%

Venture Capital

2.58%

Bank and Trust

1.06%

Pension Fund

0.13%

其他

6.78%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

386

74.75M

90.29%

-14.30M

2025Q3

373

69.94M

127.01%

+1.23K

2025Q2

381

69.95M

127.71%

-5.27M

2025Q1

371

75.32M

126.89%

-11.89M

2024Q4

359

75.24M

109.81%

+11.20M

2024Q3

343

59.71M

126.62%

+193.11K

2024Q2

330

60.06M

120.79%

+1.75M

2024Q1

313

56.72M

108.78%

+2.51M

2023Q4

268

50.21M

76.86%

+16.41M

2023Q3

224

33.81M

98.97%

+2.98M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Cormorant Asset Management, LP

8.27M

9.98%

-60.00K

-0.72%

Dec 04, 2025

Suvretta Capital Management, LLC

6.19M

7.48%

-611.38K

-8.99%

Sep 30, 2025

Adage Capital Management, L.P.

5.56M

6.72%

-1.24M

-18.24%

Sep 30, 2025

The Vanguard Group, Inc.

3.79M

4.58%

-8.13K

-0.21%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.28M

5.17%

-316.39K

-6.88%

Sep 30, 2025

Franklin Advisers, Inc.

4.14M

5%

-130.85K

-3.07%

Sep 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

4.32%

-1.46K

-0.04%

Sep 30, 2025

TCG Crossover Management, LLC

3.57M

4.32%

--

Sep 30, 2025

Citadel Advisors LLC

2.14M

2.58%

-208.82K

-8.91%

Sep 30, 2025

Paradigm BioCapital Advisors LP

2.01M

2.42%

+2.01M

--

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

1%

Simplify Health Care ETF

0.99%

State Street SPDR S&P Pharmaceuticals ETF

0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

0.36%

Federated Hermes MDT Small Cap Core ETF

0.3%

iShares Micro-Cap ETF

0.15%

iShares Health Innovation Active ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.09%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1%

Simplify Health Care ETF

佔比0.99%

State Street SPDR S&P Pharmaceuticals ETF

佔比0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.36%

Federated Hermes MDT Small Cap Core ETF

佔比0.3%

iShares Micro-Cap ETF

佔比0.15%

iShares Health Innovation Active ETF

佔比0.15%

ProShares Ultra Nasdaq Biotechnology

佔比0.12%

Invesco Nasdaq Biotechnology ETF

佔比0.09%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

公告日期

除權除息日

類型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1